Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1298 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial
E. M. Brady,M. J. Davies,L. J. Gray,M. A. Saeed,D. Smith,W. Hanif,K. Khunti
Diabetes, Obesity and Metabolism.2014;16(6)527
[DOI]
2Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence
Saud Al Sifri,Kashif Rizvi
Diabetes Therapy.2016;7(2)221
[DOI]
3Ramadan and diabetes: What we see, learn and understand from continuous glucose monitoring
L. Monnier,A. El Azrak,N. Lessan,D. Rochd,C. Colette,F. Bonnet
Diabetes & Metabolism.2015;41(6)456
[DOI]
4Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial
Rakesh Sahay,Khadijah Hafidh,Khier Djaballah,Mathieu Coudert,Sami Azar,Naim Shehadeh,Wasim Hanif,Mohamed Hassanein
Diabetes Research and Clinical Practice.2020;163(6)108148
[DOI]
5Diabète et Ramadan: Mise au point sur les recommandations récentes
S. El Aziz,S. Skalli,A. Chadli,H. El Ghomari,A. Farouqi
Médecine des Maladies Métaboliques.2014;8(2)221
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal